Bifeprunox vs placebo for schizophrenia
| dc.contributor.author | Frey, Stephen | |
| dc.contributor.author | Green, Ghiselle | |
| dc.contributor.author | Harkness, Alexandra | |
| dc.contributor.author | McDermott, Alice | |
| dc.contributor.author | Yates, Anna | |
| dc.date.accessioned | 2017-09-20T15:57:43Z | |
| dc.date.available | 2017-09-20T15:57:43Z | |
| dc.date.issued | 2016 | |
| dc.identifier.citation | Chattopadhyay, A., Frey, S., Green, G., Harkness, A., McDermott, A. & Yates, A. (2016). Bifeprunox vs placebo for schizophrenia. Schizophrenia Bulletin, 42(4), pp.881-882. | |
| dc.identifier.other | 10.1093/schbul/sbw048 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12904/9830 | |
| dc.description.abstract | This article reviews the effects of bifeprunox compared with placebo for schizophrenia. The results from this review alone show some positive effects and favorable adverse effect profile for bifeprunox— although there are few data overall and none are of high quality. These data alone would not seem to have been enough for the FDA to make their decision to halt progress of the drug to market. One can only assume that we are missing important data. Both the FDA and the relevant pharmaceutical companies have not made all relevant data accessible. Because some of these trials also involved an additional haloperidol, olanzapine, quetiapine, or risperidone arm, these data are relevant to not only to evaluation of bifeprunox. In not making all data accessible it is hard to see how the FDA and the drug companies have fulfilled their full obligations to people with schizophrenia or their clinicians. (PsycINFO Database Record (c) 2017 APA, all rights reserved) | |
| dc.description.uri | https://academic.oup.com/schizophreniabulletin/article/42/4/881/2414073/Bifeprunox-vs-Placebo-for-Schizophrenia | |
| dc.subject | Schizophrenia | |
| dc.subject | Drug therapy | |
| dc.title | Bifeprunox vs placebo for schizophrenia | |
| dc.type | Article | |
| html.description.abstract | This article reviews the effects of bifeprunox compared with placebo for schizophrenia. The results from this review alone show some positive effects and favorable adverse effect profile for bifeprunox— although there are few data overall and none are of high quality. These data alone would not seem to have been enough for the FDA to make their decision to halt progress of the drug to market. One can only assume that we are missing important data. Both the FDA and the relevant pharmaceutical companies have not made all relevant data accessible. Because some of these trials also involved an additional haloperidol, olanzapine, quetiapine, or risperidone arm, these data are relevant to not only to evaluation of bifeprunox. In not making all data accessible it is hard to see how the FDA and the drug companies have fulfilled their full obligations to people with schizophrenia or their clinicians. (PsycINFO Database Record (c) 2017 APA, all rights reserved) |